Jacobs & Co. CA boosted its stake in shares of Bristol-Myers Squibb Co (NYSE:BMY) by 1.4% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 65,648 shares of the biopharmaceutical company’s stock after purchasing an additional 886 shares during the quarter. Jacobs & Co. CA’s holdings in Bristol-Myers Squibb were worth $2,977,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors also recently modified their holdings of the company. Financial Gravity Wealth Inc. purchased a new stake in Bristol-Myers Squibb during the 1st quarter worth about $26,000. Private Ocean LLC acquired a new position in shares of Bristol-Myers Squibb during the 1st quarter worth about $28,000. Trust Department MB Financial Bank N A acquired a new position in shares of Bristol-Myers Squibb during the 1st quarter worth about $32,000. James Investment Research Inc. boosted its position in shares of Bristol-Myers Squibb by 36.5% during the 1st quarter. James Investment Research Inc. now owns 819 shares of the biopharmaceutical company’s stock worth $39,000 after acquiring an additional 219 shares in the last quarter. Finally, Endurance Wealth Management Inc. boosted its position in shares of Bristol-Myers Squibb by 119.6% during the 2nd quarter. Endurance Wealth Management Inc. now owns 918 shares of the biopharmaceutical company’s stock worth $42,000 after acquiring an additional 500 shares in the last quarter. Institutional investors own 77.37% of the company’s stock.
Several research analysts have recently issued reports on the company. UBS Group lowered their price objective on Bristol-Myers Squibb from $55.00 to $51.00 and set a “neutral” rating for the company in a research report on Thursday, June 13th. Argus cut Bristol-Myers Squibb from a “buy” rating to a “hold” rating and set a $46.36 price objective for the company. in a research report on Monday, May 20th. Zacks Investment Research raised Bristol-Myers Squibb from a “hold” rating to a “buy” rating and set a $54.00 price objective for the company in a research report on Tuesday, May 7th. ValuEngine cut Bristol-Myers Squibb from a “sell” rating to a “strong sell” rating in a research report on Tuesday, July 2nd. Finally, Atlantic Securities raised Bristol-Myers Squibb from a “neutral” rating to an “overweight” rating and set a $63.00 price objective for the company in a research report on Wednesday. One research analyst has rated the stock with a sell rating, eight have given a hold rating and nine have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average price target of $55.88.
In other Bristol-Myers Squibb news, insider Karen Murphy Santiago sold 3,065 shares of the stock in a transaction that occurred on Thursday, May 16th. The stock was sold at an average price of $47.56, for a total transaction of $145,771.40. Following the completion of the sale, the insider now directly owns 3,066 shares of the company’s stock, valued at approximately $145,818.96. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Theodore R. Samuels II acquired 5,000 shares of the firm’s stock in a transaction on Thursday, May 16th. The shares were bought at an average cost of $47.29 per share, with a total value of $236,450.00. Following the completion of the transaction, the director now directly owns 27,000 shares in the company, valued at approximately $1,276,830. The disclosure for this purchase can be found here. 0.13% of the stock is owned by corporate insiders.
Shares of NYSE BMY traded down $0.19 during trading hours on Wednesday, reaching $46.30. The stock had a trading volume of 194,258 shares, compared to its average volume of 16,761,281. The stock has a market capitalization of $77.40 billion, a price-to-earnings ratio of 11.66, a price-to-earnings-growth ratio of 2.34 and a beta of 0.73. The company has a debt-to-equity ratio of 1.51, a quick ratio of 3.75 and a current ratio of 3.88. Bristol-Myers Squibb Co has a fifty-two week low of $42.48 and a fifty-two week high of $63.69. The business’s 50-day simple moving average is $45.29.
Bristol-Myers Squibb (NYSE:BMY) last announced its earnings results on Thursday, July 25th. The biopharmaceutical company reported $1.18 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.06 by $0.12. The firm had revenue of $6.27 billion during the quarter, compared to analysts’ expectations of $6.10 billion. Bristol-Myers Squibb had a return on equity of 47.63% and a net margin of 26.14%. The business’s revenue was up 10.0% on a year-over-year basis. During the same period in the prior year, the firm earned $1.01 EPS. Equities analysts anticipate that Bristol-Myers Squibb Co will post 4.26 EPS for the current fiscal year.
The company also recently announced a quarterly dividend, which was paid on Thursday, August 1st. Investors of record on Friday, July 5th were given a $0.41 dividend. The ex-dividend date was Wednesday, July 3rd. This represents a $1.64 dividend on an annualized basis and a dividend yield of 3.54%. Bristol-Myers Squibb’s dividend payout ratio (DPR) is presently 41.21%.
Bristol-Myers Squibb Company Profile
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.
Further Reading: What is the outlook for the FAANG stocks?
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.